Are there other aspects of the business, somewhat peculiar to the industry involved, which will give the investor important clues as to how outstanding the company may be in relation to its competition? - Philip Fisher
One of the most exciting times for bioscience investors is during a positive regulatory binary, i.e. a drug approval. As I forecasted, Global Blood Therapeutics (GBT) gained FDA approval for its lead medicine, Oxbryta. Being the first of its kind, Oxbryta has a very strong chance of dominating an untamed market.
From a trading viewpoint, the stock